4.7 Article

Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA Vaccine: A Multicenter Cohort Study

Journal

CLINICAL INFECTIOUS DISEASES
Volume -, Issue -, Pages -

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciad175

Keywords

SARS-CoV-2; immunity; immunocompromised; prospective; mRNA vaccine

Ask authors/readers for more resources

This multicenter cohort study found that organ transplant recipients had suboptimal neutralization to the booster vaccine against BA.4/5. Age, mycophenolate, and prednisone use were factors that impacted the neutralization response. However, vaccination did induce T-cell responses in the majority of patients.
This prospective, multicenter cohort study of organ transplant recipients showed suboptimal neutralization to booster vaccine against BA.4/5, which is especially impacted by age and mycophenolate and prednisone use. Vaccination produced T-cell responses in the majority of patients. Background In solid organ transplant (SOT) recipients, the primary vaccination series against Coronavirus Disease 2019 is 3 doses followed by boosters. We determined whether a fourth dose booster induced Omicron BA.4/5 neutralizing antibodies (nAbs) and T cells in a large multicenter cohort study. Methods Serum was collected 4-6 weeks post-third and post-fourth doses of messenger RNA vaccine in 222 SOT recipients. nAbs were measured using a pseudovirus neutralization assay that targeted the Omicron BA.4/5 spike protein. A subset underwent T-cell testing. Results The median age of the cohort was 63 years (interquartile range [IQR], 50-68) with 61.7% men. BA.4/5 nAb detection increased from 26.6% (59 of 222) post-third dose to 53.6% (119 of 222) post-fourth dose (P < .0001). In patients with breakthrough infection prior to the fourth dose (n = 27), nAbs were detected in 77.8% and median nAb titers were significantly higher compared with those with 4 vaccine doses alone (P < .0001). Factors associated with a low BA.4/5 neutralization response after the fourth dose were older age (odds ratio [OR], 0.96; 95% confidence interval [CI], .94-.99), mycophenolate use (OR, 0.39; 95% CI, .20-.77) and prednisone use (OR, 0.34; 95% CI, .18-.63), and vaccine type (OR, 0.72; 95% CI, .51-.99), while breakthrough infection prior to the fourth dose (OR, 3.6; 95% CI, 1.3-9.9) was associated with a greater nAb response. Polyfunctional BA.4/5-specific CD4(+) T cells significantly increased after 4 doses and were identified in 76.9% of patients at a median frequency of 213/10(6) cells (IQR, 98-650). Conclusions In summary, a booster significantly increases BA.4/5-specific neutralization and polyfunctional CD4(+) T-cell responses, suggesting protection from severe disease even with new Omicron variants. However, SOT recipients who are older and on mycophenolate and prednisone need additional preventative strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available